Your search found 3 Results

  1. 1

    Hormonal contraception and HIV. Technical update.

    United States. Agency for International Development [USAID]; United States. Centers for Disease Control and Prevention [CDC]; United States. Agency for International Development [USAID]. Office of Population and Reproductive Health

    [Washington, D.C.], United States Agency for International Development [USAID], 2017 Jul. 3 p.

    The purpose of this technical update is to summarize current evidence and the World Health Organization (WHO) revised guidance regarding use of hormonal contraception (HC) by women at high risk of acquiring HIV. On March 2, 2017, WHO issued revised guidance on the use of progestogen-only injectables (norethisterone enanthate [NET-EN] and depot medroxyprogesterone acetate [DMPA], in both intramuscular [IM] and subcutaneous [SC] forms) by women at high risk of HIV acquisition. The recommendation was previously a Category 1 with a clarification, meaning there was no restriction on the use of the progestogen-only injectables, but women at high risk of HIV should be informed that use of those contraceptive methods may or may not increase risk of HIV acquisition. With the revised guidance, progestogen-only injectables are now classified as Category 2 for women at high risk of HIV acquisition. (excerpt)
    Add to my documents.
  2. 2
    Peer Reviewed

    The challenge of introducing the female condom for dual protection. [Desafío de introducir el preservativo femenino para la protección doble]

    Warren M; Morris C

    Sexual Health Exchange. 2002; (2):9-10.

    In 1997, the Female Health Company (FHC) launched the female condom. Since then, FHC has gained considerable experience introducing this new product worldwide. A wide range of acceptability studies and field projects in many different countries, and social and economic settings have shown that the female condom is acceptable to a number of women and men. However, translating this acceptability into protected sex acts remains a major challenge. Based on lessons learned from pilot projects in 17 countries, FHC and Marie Stopes International recently initiated a new female condom introduction strategy in a number of Latin American countries. (author's)
    Add to my documents.
  3. 3

    Joint WHO / UNAIDS / UNFPA policy statement: Dual protection against unwanted pregnancy and sexually transmitted infections, including HIV.

    World Health Organization [WHO]; Joint United Nations Programme on HIV / AIDS [UNAIDS]; United Nations Population Fund [UNFPA]

    [Unpublished] 2000 Sep 29. [2] p.

    Family planning programs have made significant progress in the provision of contraception to reduce unwanted pregnancies. However, sexually transmitted infections (STIs), including HIV, continue to spread epidemically throughout the world, especially in developing countries. This includes the transmission of HIV from mother to child in pre and post-natal settings. Given this reality, prevention of these infections must be reinforced in the context of the provision of reproductive health and family planning services, and the concept of dual protection, i.e., protection against both unplanned pregnancy and STIs/HIV, must be greatly expanded. (excerpt)
    Add to my documents.